JPY 4,785.00
+0.38%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 9Sep 14Sep 17
Key dataSep 17, 2026
OpenJPY 4,884.00
From 52W high−10.09%
Volume1.52M
Market capJPY 1.35T
P/E (TTM)31.9x
P/S (TTM)1.6x
Div yield3.34%
Key dataSep 17, 2026
Open
JPY 4,884.00
From 52W high
−10.09%
Volume
1.52M
Market cap
JPY 1.35T
ValuationView details →
P/E (Fwd)
23.0x
EV/EBITDA
13.8x
P/E (TTM)
31.9x
RSI (14)
63.1
MomentumView details →
1D Return
+0.38%
YTD Return
+6.29%
Similar companies
Latest newsMore news →
Eisai and Biogen received Japanese manufacturing and marketing approval for a subcutaneous injection formulation of their Alzheimer's drug lecanemab (brand name Leqembi), which can be administered at home once weekly with a dedicated pen injector.2d agoExaWizards announced that its AI interactive role-playing service ExaBase Roleplay has been adopted by Eisai.3d agoEisai announced that China approved LEQEMBI (lecanemab) subcutaneous formulation as an initiation treatment for early Alzheimer's disease, enabling at-home administration.15d ago